Literature DB >> 30630845

BID-ding on necroptosis in MDS.

Ben A Croker1, Michelle A Kelliher2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30630845      PMCID： PMC6328628          DOI： 10.1182/blood-2018-11-886242

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4.

Authors:  Malek Najjar; Danish Saleh; Matija Zelic; Shoko Nogusa; Saumil Shah; Albert Tai; Joshua N Finger; Apostolos Polykratis; Peter J Gough; John Bertin; Michael Whalen; Manolis Pasparakis; Siddharth Balachandran; Michelle Kelliher; Alexander Poltorak; Alexei Degterev
Journal:  Immunity       Date:  2016-07-05       Impact factor: 31.745

2.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Authors:  Ashley A Basiorka; Kathy L McGraw; Erika A Eksioglu; Xianghong Chen; Joseph Johnson; Ling Zhang; Qing Zhang; Brittany A Irvine; Thomas Cluzeau; David A Sallman; Eric Padron; Rami Komrokji; Lubomir Sokol; Rebecca C Coll; Avril A B Robertson; Matthew A Cooper; John L Cleveland; Luke A O'Neill; Sheng Wei; Alan F List
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

3.  Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner.

Authors:  Stephanie A Conos; Kaiwen W Chen; Dominic De Nardo; Hideki Hara; Lachlan Whitehead; Gabriel Núñez; Seth L Masters; James M Murphy; Kate Schroder; David L Vaux; Kate E Lawlor; Lisa M Lindqvist; James E Vince
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

4.  Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice.

Authors:  Patrice N Wagner; Qiong Shi; Christi T Salisbury-Ruf; Jing Zou; Michael R Savona; Yuri Fedoriw; Sandra S Zinkel
Journal:  Blood       Date:  2018-11-09       Impact factor: 22.113

5.  Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Malin Hultcrantz; Åsa R Derolf; Ola Landgren; Lynn R Goldin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

6.  Induction of myelodysplasia by myeloid-derived suppressor cells.

Authors:  Xianghong Chen; Erika A Eksioglu; Junmin Zhou; Ling Zhang; Julie Djeu; Nicole Fortenbery; Pearlie Epling-Burnette; Sandra Van Bijnen; Harry Dolstra; John Cannon; Je-in Youn; Sarah S Donatelli; Dahui Qin; Theo De Witte; Jianguo Tao; Huaquan Wang; Pingyan Cheng; Dmitry I Gabrilovich; Alan List; Sheng Wei
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis.

Authors:  James A Rickard; Joanne A O'Donnell; Joseph M Evans; Najoua Lalaoui; Ashleigh R Poh; TeWhiti Rogers; James E Vince; Kate E Lawlor; Robert L Ninnis; Holly Anderton; Cathrine Hall; Sukhdeep K Spall; Toby J Phesse; Helen E Abud; Louise H Cengia; Jason Corbin; Sandra Mifsud; Ladina Di Rago; Donald Metcalf; Matthias Ernst; Grant Dewson; Andrew W Roberts; Warren S Alexander; James M Murphy; Paul G Ekert; Seth L Masters; David L Vaux; Ben A Croker; Motti Gerlic; John Silke
Journal:  Cell       Date:  2014-05-08       Impact factor: 41.582

8.  Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis.

Authors:  Justine E Roderick; Nicole Hermance; Matija Zelic; Matthew J Simmons; Apostolos Polykratis; Manolis Pasparakis; Michelle A Kelliher
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

Review 9.  Necroptosis-independent signaling by the RIP kinases in inflammation.

Authors:  Kenta Moriwaki; Francis Ka-Ming Chan
Journal:  Cell Mol Life Sci       Date:  2016-04-05       Impact factor: 9.261

10.  Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.

Authors:  Kathleen Weisel; Nicola E Scott; Debra J Tompson; Bartholomew J Votta; Sujith Madhavan; Kat Povey; Allen Wolstenholme; Monica Simeoni; Todd Rudo; Lauren Richards-Peterson; Tarjinder Sahota; J Gene Wang; John Lich; Joshua Finger; Adeline Verticelli; Michael Reilly; Peter J Gough; Philip A Harris; John Bertin; Mei-Lun Wang
Journal:  Pharmacol Res Perspect       Date:  2017-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.